综合一区欧美国产,99国产麻豆免费精品,九九精品黄色录像,亚洲激情青青草,久久亚洲熟妇熟,中文字幕av在线播放,国产一区二区卡,九九久久国产精品,久久精品视频免费

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

China becomes key strategic market for CSL

By ZHOU WENTING in Shanghai | China Daily | Updated: 2025-12-18 09:08
Share
Share - WeChat

Australian biopharmaceutical company CSL has designated China as one of its most important strategic markets worldwide, a milestone highlighted by a significant expansion of both its workforce and investment in the country, said a senior executive.

Since 1986, CSL — a century-old firm — has supplied human albumin to Chinese patients, with a large proportion of the company's albumin products supplied to the China market. According to data released by information consultancy IQVIA in September, CSL's human albumin has maintained the largest market share in China.

Wang Yu, general manager of CSL China

"As the world's second-largest pharmaceutical market, China, a market that we've been deeply involved with for 40 years, is a critical growth engine within CSL's global blueprint," said Wang Yu, general manager of CSL China, during a recent interview in Shanghai.

"Looking ahead at the vast market potential and opportunities, CSL will focus on 'new products, new collaborations, and new efficiency', driving sustainable and high-quality growth," she said.

For four decades, CSL has been committed to addressing the needs of patients with rare and severe diseases in China.

Human albumin, derived from human plasma, is used clinically for emergency treatment of hypovolemia, severe hypo-albuminemia, neonatal hyperbilirubinemia, and acute respiratory distress syndrome, among others.

Since 2018, CSL has experienced significant growth in China, according to Wang. Within regulatory limits, the company has supported medical institutions and clinical experts, contributing to the publication of several treatment guidelines and consensus documents, thus advancing the standardization and rational use of human albumin in the country.

In response to the Guangdong-Hong Kong-Macao Greater Bay Area's special access policy for Hong Kong and Macao drugs and medical devices that allows designated hospitals in the bay area to use Hong Kong-approved drugs and medical devices, CSL has facilitated the introduction of anti-D immunoglobulin to three medical institutions on the Chinese mainland, benefiting over 3,000 pregnant women with rare Rh-negative blood.

In March, Paul McKenzie, CEO and managing director of CSL, emphasized at the China Development Forum that China is a crucial strategic market for the company. He reiterated the company's commitment to deepening its presence in China, and fostering innovation with upstream and downstream partners to support the development of China's healthcare sector.

"The strategic market designation of China together with other markets, such as the United States and Germany, means our investment in China will be larger, more sustained, and more committed. Our workforce has grown considerably this year and continues to grow," said Wang.

Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
宁城县| 乐山市| 博兴县| 张北县| 常州市| 克山县| 湖南省| 河源市| 托克托县| 景洪市| 卢氏县| 滨海县| 天柱县| 锡林郭勒盟| 盐城市| 茌平县| 宜州市| 娄底市| 兴业县| 饶平县| 益阳市| 临城县| 河北省| 牙克石市| 合山市| 金坛市| 大厂| 南通市| 聂拉木县| 乌鲁木齐市| 延安市| 舟山市| 伊宁县| 绥棱县| 托克逊县| 长汀县| 将乐县| 浦城县| 西华县| 柘城县| 临海市|